

Lale Kostakoglu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/228871/publications.pdf>

Version: 2024-02-01

48
papers

2,978
citations

394421

19
h-index

243625

44
g-index

48
all docs

48
docs citations

48
times ranked

3822
citing authors

#	ARTICLE	IF	CITATIONS
1	Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study. <i>Haematologica</i> , 2022, 107, 1633-1642.	3.5	21
2	A prognostic model integrating PET-derived metrics and image texture analyses with clinical risk factors from GOYA. <i>EJHaem</i> , 2022, 3, 406-414.	1.0	6
3	Follicular Lymphoma Treated with First-Line Immunochemotherapy: A Review of PET/CT in Patients Who Did Not Achieve a Complete Metabolic Response in the GALLIUM Study. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1149-1154.	5.0	3
4	Brain and blood biomarkers of tauopathy and neuronal injury in humans and rats with neurobehavioral syndromes following blast exposure. <i>Molecular Psychiatry</i> , 2021, 26, 5940-5954.	7.9	56
5	End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA. <i>Blood Advances</i> , 2021, 5, 1283-1290.	5.2	21
6	Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412. <i>Journal of Clinical Oncology</i> , 2021, 39, 1329-1338.	1.6	60
7	Convolutional Neural Networks for Automated PET/CT Detection of Diseased Lymph Node Burden in Patients with Lymphoma. <i>Radiology: Artificial Intelligence</i> , 2020, 2, e200016.	5.8	37
8	Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial. <i>Blood</i> , 2020, 135, 2224-2234.	1.4	62
9	Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYA. <i>Blood Advances</i> , 2020, 4, 1589-1593.	5.2	16
10	Comparison of 11 automated PET segmentation methods in lymphoma. <i>Physics in Medicine and Biology</i> , 2020, 65, 235019.	3.0	19
11	SWOG S1826: A Phase III, Randomized Study of Nivolumab Plus AVD or Brentuximab Vedotin Plus AVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 23-24.	1.4	9
12	End-of-Treatment PET/Computed Tomography Response in Diffuse Large B-Cell Lymphoma. <i>PET Clinics</i> , 2019, 14, 307-315.	3.0	8
13	PET-Derived Quantitative Metrics for Response and Prognosis in Lymphoma. <i>PET Clinics</i> , 2019, 14, 317-329.	3.0	16
14	Efficacy and Safety of High-Specific-Activity ¹³¹ I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma. <i>Journal of Nuclear Medicine</i> , 2019, 60, 623-630.	5.0	193
15	The Impact of Positron Emission Tomography with ¹⁸ F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial. <i>Journal of Urology</i> , 2019, 201, 322-331.	0.4	113
16	Potential Factors That Impact Lenalidomide/R-CHOP Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies. <i>Blood</i> , 2019, 134, 4092-4092.	1.4	4
17	A core laboratory approach to large-scale radiomics and machine-learning prediction of DLBCL outcomes after first-line treatment using results from the phase III GOYA study. <i>Journal of Clinical Oncology</i> , 2019, 37, e19042-e19042.	1.6	0
18	A Prognostic Model Integrating PET-Derived Quantitative Parameters and Image Texture Analyses Using Radiomics in a Large Prospective Phase III Trial, GOYA. <i>Blood</i> , 2019, 134, 883-883.	1.4	1

#	ARTICLE	IF	CITATIONS
19	Complete Response Status According to RECIL 2017 Criteria Shows High Concordance with Lugano 2014 Criteria and Is Highly Prognostic for Outcome in Previously Untreated Patients with CD20-Positive Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2019, 134, 489-489.	1.4	2
20	Patient-Level Meta-Analysis of End-of-Therapy PET-CR as a Surrogate Endpoint for PFS and OS in Patients with Previously Untreated DLBCL: Implications for Clinical Trial Design. <i>Blood</i> , 2019, 134, 4101-4101.	1.4	0
21	Guest Editorial. <i>Seminars in Nuclear Medicine</i> , 2018, 48, 2-3.	4.6	0
22	Metabolic Tumor Volume Metrics in Lymphoma. <i>Seminars in Nuclear Medicine</i> , 2018, 48, 50-66.	4.6	75
23	Quantitative comparison of pre-therapy ^{99m} Tc-macroaggregated albumin SPECT/CT and post-therapy PET/MR studies of patients who have received intra-arterial radioembolization therapy with ⁹⁰ Y microspheres. <i>European Journal of Radiology</i> , 2018, 109, 57-61.	2.6	7
24	Comparison of PET/CT and PET/MR imaging and dosimetry of yttrium-90 (⁹⁰ Y) in patients with unresectable hepatic tumors who have received intra-arterial radioembolization therapy with ⁹⁰ Y microspheres. <i>EJNMMI Physics</i> , 2018, 5, 23.	2.7	9
25	Feasibility and diagnostic performance of hybrid PET/MRI compared with PET/CT for gynecological malignancies: a prospective pilot study. <i>Abdominal Radiology</i> , 2018, 43, 3462-3467.	2.1	28
26	Updating the role of FDG PET/CT for evaluation of lung cancer manifesting in nonsolid nodules. <i>Clinical Imaging</i> , 2018, 52, 157-162.	1.5	2
27	CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. <i>Blood</i> , 2018, 132, 1013-1021.	1.4	90
28	The Prognostic Impact of Baseline Positron Emission Tomography (PET) Imaging in Untreated High Risk (HR) Follicular Lymphoma (FL): Analysis from E2408, the Bortezomib Induction or Novel Imidazole Continuation (BIONIC) Study. <i>Blood</i> , 2018, 132, 1615-1615.	1.4	1
29	Bone Marrow Biopsy Impacts Response Assessment in a Minority of Patients with Follicular Lymphoma and Diffuse Large B-Cell Lymphoma Treated with Immunotherapy: Results from the Randomized Phase III GALLIUM and GOYA Trials. <i>Blood</i> , 2018, 132, 1605-1605.	1.4	1
30	Surveillance Imaging in HPV-related Oropharyngeal Cancer. <i>Anticancer Research</i> , 2018, 38, 1525-1529.	1.1	9
31	Comparison of standardized uptake value ratio calculations in amyloid positron emission tomography brain imaging. <i>World Journal of Nuclear Medicine</i> , 2018, 17, 21-26.	0.5	13
32	Reader Training for the Restaging of Biochemically Recurrent Prostate Cancer Using ¹⁸ F-Fluciclovine PET/CT. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1596-1602.	5.0	33
33	Baseline PET-Derived Metabolic Tumor Volume Metrics Predict Progression-Free and Overall Survival in DLBCL after First-Line Treatment: Results from the Phase 3 GOYA Study. <i>Blood</i> , 2017, 130, 824-824.	1.4	21
34	Optimization of yttrium-90 PET for simultaneous PET/MR imaging: A phantom study. <i>Medical Physics</i> , 2016, 43, 4768-4774.	3.0	8
35	Lymph nodes can accurately be measured on PET-CT for lymphoma staging/restaging without a concomitant contrast enhanced CT scan. <i>Leukemia and Lymphoma</i> , 2016, 57, 1083-1093.	1.3	3
36	PET-derived metabolic volume metrics in lymphoma. <i>Clinical and Translational Imaging</i> , 2015, 3, 331-341.	2.1	5

#	ARTICLE	IF	CITATIONS
37	A Phase II Study of ^{18}F -Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIIN 6688. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1681-1689.	5.0	73
38	The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease. <i>Hematology American Society of Hematology Education Program</i> , 2014, 2014, 135-143.	2.5	10
39	Current role of FDG PET/CT in lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1004-1027.	6.4	63
40	State of the art imaging of multiple myeloma: Comparative review of FDG PET/CT imaging in various clinical settings. <i>European Journal of Radiology</i> , 2014, 83, 2203-2223.	2.6	78
41	Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. <i>Journal of Clinical Oncology</i> , 2014, 32, 3048-3058.	1.6	1,269
42	The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease. <i>Blood</i> , 2014, 124, 3356-3364.	1.4	36
43	International Validation Study for Interim PET in ABVD-Treated, Advanced-Stage Hodgkin Lymphoma: Interpretation Criteria and Concordance Rate Among Reviewers. <i>Journal of Nuclear Medicine</i> , 2013, 54, 683-690.	5.0	267
44	Interim [^{18}F]fluorodeoxyglucose positron emission tomography imaging in stage II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?. <i>Leukemia and Lymphoma</i> , 2012, 53, 2143-2150.	1.3	54
45	Novel PET Radiotracers for Potential Use in Management of Lymphoma. <i>PET Clinics</i> , 2012, 7, 83-117.	3.0	7
46	Interim results of an open-label, single-arm trial of ultratrace I-131-iobenguane in patients with metastatic pheochromocytoma/paraganglioma (Pheo).. <i>Journal of Clinical Oncology</i> , 2012, 30, e13592-e13592.	1.6	3
47	FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. <i>Cancer</i> , 2006, 107, 2678-2687.	4.1	165
48	PET-CR as a potential surrogate endpoint in untreated DLBCL: meta-analysis and implications for clinical trial design. <i>Leukemia and Lymphoma</i> , 0, , 1-16.	1.3	1